A large study suggests that older adults with breast or prostate cancer and metabolic syndrome have poorer overall, cancer-specific, and cardiovascular survival. Learn what the findings mean and why managing metabolic health may be important during cancer care.
- Older adults with metabolic syndrome had higher overall mortality after breast or prostate cancer
- Cardiovascular and liver-related deaths were also more common among patients with metabolic syndrome
- Researchers say managing metabolic health may become an important part of comprehensive cancer care
Metabolic syndrome, a cluster of conditions that includes obesity, high blood pressure, abnormal cholesterol levels, and diabetes, is already known to increase the risk of heart disease and stroke. Now, a large study suggests it may also be linked to poorer survival among older adults diagnosed with breast or prostate cancer (1✔ ✔Trusted Source
Metabolic syndrome is associated with increased mortality in patients with breast or prostate cancer
).
The findings, published in Scientific Reports, indicate that patients with metabolic syndrome were more likely to die from cancer, cardiovascular disease, and other causes than those without the condition. Although the study found a strong association, it does not prove that metabolic syndrome directly causes poorer outcomes.
Advertisement
What Is Metabolic Syndrome?
Metabolic syndrome is diagnosed when a person has three or more of the following risk factors:
- High blood pressure
- High blood sugar or type 2 diabetes
- High triglyceride levels
- Low HDL (“good”) cholesterol
- Excess abdominal fat
Together, these conditions increase chronic inflammation and insulin resistance, both of which may influence cancer progression and overall health.
Advertisement
How Was the Study Conducted?
Researchers analyzed data from the SEER-Medicare database, including:
- 104,599 older adults with breast cancer
- 96,005 older adults with prostate cancer
Participants were aged 66 years or older and were diagnosed between 2008 and 2019. About 28% of breast cancer patients and 31% of prostate cancer patients met the criteria for metabolic syndrome.
Researchers followed participants after diagnosis and evaluated deaths from:
- Any cause
- Cancer
- Cardiovascular disease
- Liver failure
Advertisement
Study at a Glance
| Feature | Details |
|---|---|
| Study design | Retrospective observational study |
| Data source | SEER-Medicare database |
| Breast cancer patients | 104,599 |
| Prostate cancer patients | 96,005 |
| Age | 66 years and older |
| Journal | Scientific Reports |
What Did the Researchers Find?
Patients with metabolic syndrome had significantly poorer survival than those without it.
Overall Mortality
Compared with patients without metabolic syndrome:
- Breast cancer: Overall risk of death was about 2 times higher(HR 2.03).
- Prostate cancer: Overall risk of death was about 2.2 times higher (HR 2.21).
Cancer-Specific Mortality
Metabolic syndrome was also linked to:
- 30% higher risk of death from breast cancer (HR 1.30)
- 32% higher risk of death from prostate cancer (HR 1.32)
Cardiovascular Mortality
Patients with metabolic syndrome were more than twice as likely to die from cardiovascular disease compared with those without metabolic syndrome.
The study also found higher liver failure-related mortality, although these estimates were based on fewer events and were therefore less precise.
Key Findings
| Outcome | Breast Cancer | Prostate Cancer |
|---|---|---|
| Overall mortality | HR 2.03 | HR 2.21 |
| Cancer-specific mortality | HR 1.30 | HR 1.32 |
| Cardiovascular mortality | HR 2.27 | HR 2.46 |
Why Might Metabolic Syndrome Affect Cancer Outcomes?
Researchers believe several biological mechanisms could contribute to poorer outcomes, including:
- Chronic inflammation
- Insulin resistance
- Elevated insulin and growth factor signaling
- Hormonal changes
- Obesity-related metabolic dysfunction
These factors may create an environment that supports cancer progression while also increasing the risk of cardiovascular disease. However, the current study was not designed to determine exactly how these mechanisms influence survival.
What Are the Study’s Limitations?
The researchers caution that the findings should be interpreted carefully. The study:
- Was observational and cannot prove cause and effect
- Identified metabolic syndrome using insurance claims rather than direct clinical measurements
- Included only adults aged 66 years and older
- May not apply to younger patients or those without Medicare coverage
Interestingly, a sensitivity analysis that looked only at metabolic syndrome documented before cancer diagnosis did not find a significant association with cancer-specific mortality, suggesting the timing of metabolic changes may be important.
What This Means for You
This large study suggests that metabolic syndrome may be an important marker of poorer survival among older adults with breast or prostate cancer. While the findings do not prove that metabolic syndrome causes worse outcomes, they reinforce the importance of managing blood pressure, blood sugar, cholesterol, and body weight alongside standard cancer treatment.
Integrating metabolic health into routine oncology care may help improve overall health and reduce cardiovascular complications, although further research is needed to determine whether treating metabolic syndrome directly improves cancer survival.
Frequently Asked Questions
Q: What is metabolic syndrome?
A: Metabolic syndrome is a group of conditions-including obesity, high blood pressure, high blood sugar, abnormal cholesterol levels, and high triglycerides-that increase the risk of cardiovascular disease and type 2 diabetes.
Q: Does metabolic syndrome increase cancer mortality?
A: This study found that older adults with breast or prostate cancer and metabolic syndrome had higher overall and cancer-specific mortality, although it does not prove a direct causal relationship.
Q: Why might metabolic syndrome affect cancer outcomes?
A: Chronic inflammation, insulin resistance, hormonal changes, and obesity-related metabolic dysfunction may contribute to cancer progression and poorer overall health.
Q: Can treating metabolic syndrome improve cancer survival?
A: It is not yet known. Researchers say more clinical studies are needed to determine whether improving metabolic health directly enhances cancer outcomes.
Q: Who should be screened for metabolic syndrome?
A: People with obesity, type 2 diabetes, high blood pressure, abnormal cholesterol levels, or a large waist circumference should discuss metabolic risk assessment with their healthcare provider, especially if they have been diagnosed with cancer.
Reference:
- Metabolic syndrome is associated with increased mortality in patients with breast or prostate cancer – (https://www.nature.com/articles/s41598-026-58830-2)
Source-Medindia